Related Experiment Videos
[Acute myelomonocytic leukemia with abnormal eosinophils]
Nouvelle Revue Francaise D'Hematologie
|January 1, 1987
Summary
Acute myelomonocytic leukemia with abnormal bone marrow eosinophils (LAM4 Eo) and chromosome 16 abnormalities show a significantly better prognosis. Patients experience longer remissions and survival compared to other forms of LAM4.
Area of Science:
- Hematology
- Oncology
- Genetics
Context:
- Acute myelomonocytic leukemia (AML) is a heterogeneous disease.
- A specific subtype, LAM4 Eo, is characterized by abnormal bone marrow eosinophils.
- The prognostic significance of these features, particularly chromosome 16 abnormalities, requires elucidation.
Purpose:
- To evaluate the clinical presentation, cytogenetic findings, and treatment outcomes of patients with LAM4 Eo.
- To compare the prognosis of LAM4 Eo with LAM4 without abnormal bone marrow eosinophils.
- To establish LAM4 Eo as a distinct entity within AML.
Summary:
- Thirty-two patients with LAM4 Eo treated since 1977 were analyzed.
- Chromosome 16 abnormalities were present in 14 of 22 evaluable cases.
- Median remission duration was 46 months, and survival was not reached, significantly outperforming LAM4 without Eo (12 months remission, 14 months survival).
- Eight patients achieved long-term remission without further therapy.
Impact:
- LAM4 Eo represents a distinct AML subtype with unique hematological and genetic features.
- The presence of chromosome 16 abnormalities is associated with a favorable prognosis in LAM4 Eo.
- These findings support tailored treatment strategies and improved outcomes for patients with LAM4 Eo.